Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study.

IF 5.4 2区医学 Q1 IMMUNOLOGY

BioDrugs Pub Date : 2024-11-17 DOI:10.1007/s40259-024-00689-8

Yongtai Cho, Suneun Park, Kyungyeon Jung, Jeong-Eun Lee, Jieun Woo, Ju Hwan Kim, Ju-Young Shin

{"title":"Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study.","authors":"Yongtai Cho, Suneun Park, Kyungyeon Jung, Jeong-Eun Lee, Jieun Woo, Ju Hwan Kim, Ju-Young Shin","doi":"10.1007/s40259-024-00689-8","DOIUrl":null,"url":null,"abstract":"Background: Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limited. We therefore assessed the risk of PsA associated with interleukin (IL)-23 inhibitor, IL-17 inhibitor, or IL-12/23 inhibitor use compared with tumor necrosis factor (TNF) inhibitor use among patients with psoriasis.Methods: This population-based cohort study used the nationwide claims database from South Korea (2007-2023). New users of IL or TNF inhibitors with psoriasis who did not have PsA or other inflammatory arthritis were categorized into each class of the IL inhibitors for comparison with TNF inhibitor users. The outcome measured was the development of incident PsA. We calculated multinomial overlap weights to balance predefined covariates. Hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models.Results: We identified 9499 patients with psoriasis (mean age 45.1 years; 33.6% female), of whom 3913 (41.2%), 2126 (22.4%), 2773 (28.8%), and 727 (7.7%) were exposed to IL-23 inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, and TNF inhibitor, respectively. PsA developed in 281 (3.0%) patients during 23,275 person-years. The weighted HR for any IL inhibitors was 0.40 (95% CI 0.25-0.62), with specific HRs of 0.22 (95% CI 0.13-0.37), 0.47 (95% CI 0.28-0.80), and 0.46 (95% CI 0.29-0.74) for IL-23 inhibitor, IL-17 inhibitor, and IL-12/23 inhibitor, respectively. IL-23 inhibitors exhibited the greatest rate difference of - 2.61 (95% CI - 3.67 to - 1.55) cases of PsA per 100 person-years.Conclusions: The use of IL inhibitors, particularly IL-23 inhibitors, compared with TNF inhibitors, was associated with a lower risk of developing PsA.","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioDrugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40259-024-00689-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limited. We therefore assessed the risk of PsA associated with interleukin (IL)-23 inhibitor, IL-17 inhibitor, or IL-12/23 inhibitor use compared with tumor necrosis factor (TNF) inhibitor use among patients with psoriasis.

Methods: This population-based cohort study used the nationwide claims database from South Korea (2007-2023). New users of IL or TNF inhibitors with psoriasis who did not have PsA or other inflammatory arthritis were categorized into each class of the IL inhibitors for comparison with TNF inhibitor users. The outcome measured was the development of incident PsA. We calculated multinomial overlap weights to balance predefined covariates. Hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models.

Results: We identified 9499 patients with psoriasis (mean age 45.1 years; 33.6% female), of whom 3913 (41.2%), 2126 (22.4%), 2773 (28.8%), and 727 (7.7%) were exposed to IL-23 inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, and TNF inhibitor, respectively. PsA developed in 281 (3.0%) patients during 23,275 person-years. The weighted HR for any IL inhibitors was 0.40 (95% CI 0.25-0.62), with specific HRs of 0.22 (95% CI 0.13-0.37), 0.47 (95% CI 0.28-0.80), and 0.46 (95% CI 0.29-0.74) for IL-23 inhibitor, IL-17 inhibitor, and IL-12/23 inhibitor, respectively. IL-23 inhibitors exhibited the greatest rate difference of - 2.61 (95% CI - 3.67 to - 1.55) cases of PsA per 100 person-years.

Conclusions: The use of IL inhibitors, particularly IL-23 inhibitors, compared with TNF inhibitors, was associated with a lower risk of developing PsA.

查看原文本刊更多论文

银屑病生物疗法对银屑病关节炎发展的影响：基于人群的队列研究。

背景：比较各种治疗银屑病的生物制剂对银屑病关节炎（PsA）进展的影响的证据很有限。因此，我们评估了银屑病患者使用白细胞介素（IL）-23抑制剂、IL-17抑制剂或IL-12/23抑制剂与使用肿瘤坏死因子（TNF）抑制剂的相关PsA风险：这项基于人群的队列研究使用了韩国全国范围内的索赔数据库（2007-2023 年）。将未患有 PsA 或其他炎症性关节炎的银屑病 IL 或 TNF 抑制剂新使用者归入 IL 抑制剂的各个类别，以便与 TNF 抑制剂使用者进行比较。测量的结果是PsA的发病情况。我们计算了多项式重叠权重，以平衡预定义的协变量。使用 Cox 比例危险度模型计算危险度比（HR）和 95% 置信区间（CI）：我们发现了9499名银屑病患者（平均年龄45.1岁；33.6%为女性），其中3913人（41.2%）、2126人（22.4%）、2773人（28.8%）和727人（7.7%）分别接触过IL-23抑制剂、IL-17抑制剂、IL-12/23抑制剂和TNF抑制剂。在23,275人年中，有281名患者（3.0%）发生了PsA。任何IL抑制剂的加权HR为0.40（95% CI 0.25-0.62），IL-23抑制剂、IL-17抑制剂和IL-12/23抑制剂的特定HR分别为0.22（95% CI 0.13-0.37）、0.47（95% CI 0.28-0.80）和0.46（95% CI 0.29-0.74）。IL-23抑制剂的发病率差异最大，为每100人年-2.61（95% CI-3.67至-1.55）例PsA：结论：与 TNF 抑制剂相比，使用 IL 抑制剂（尤其是 IL-23 抑制剂）与较低的 PsA 患病风险相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BioDrugs 医学-免疫学

CiteScore

12.60

自引率

2.90%

发文量

审稿时长

>12 weeks

期刊介绍： An essential resource for R&D professionals and clinicians with an interest in biologic therapies. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.